Tubular obstruction induced polycystin upregulation is pro-fibrotic and induced a severe cystic phenotype in adult mice with autosomal dominant polycystic kidney disease: the coexistence of polycystin loss and gain function in ADPKD

Ming Wu1,2,3, *, Yanzhe Wang1,2,3, *, Ying Jing4, *, Dongping Chen1,2,3*, Yufeng Xing1,2,3, Yanfang Bai1,2,3, Di Huang1,2,3, Yijing Zhou5, Jinghua Hu6, Shougang Zhuang7, Chaoyang Ye1,2,3#

1Department of Nephrology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

2TCM Institute of Kidney Disease of Shanghai University of Traditional Chinese Medicine

3Key Laboratory of Liver and Kidney Diseases, Ministry of Education, Shanghai Key Laboratory of Traditional Chinese Clinical Medicine

4Department of Nephrology, The 960th Hospital of the PLA Joint Logistics Support Force

5Department of Nephrology, Jiaxing Hospital of Traditional Chinese Medicine, Zhejiang Province

6Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, USA; Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA; Mayo Clinic Robert M. and Billie Kelley Pirnie Translational Polycystic Kidney Disease Center, Mayo Clinic, Rochester, MN, USA.

7Department of Medicine, Rhode Island Hospital and Alpert Medical School, Brown University, Providence, RI, R02903, USA.
*These authors contributed equally to this paper.

**Running head:** Polycystin promotes fibrosis and cyst growth

# Corresponding Author 1: Prof. Chaoyang Ye, Department of Nephrology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, No.528 Zhangheng Road, Pudong District, Shanghai 201203, PR China. Fax: (0086)-21-20256182, E-mail: yechaoyang63@126.com

Corresponding Author 2: Dr. Ming Wu, Department of Nephrology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, No.528 Zhangheng Road, Pudong District, Shanghai 201203, PR China. Fax: (0086)-21-20256182, E-mail: mingwunl@126.com

**Keywords:** Polycystin; renal tubulointerstitial fibrosis; primary cilia; ADPKD;

**Research highlights:**

- Polycystin1 and polycystin-2 are up-regulated in fibrotic kidneys
- Inhibition or deletion of polycystins inhibits EMT and attenuates renal tubulointerstitial fibrosis
- Upregulation of polycystin1 or polycystin-2 is positively correlated with fibrosis progression and renal cyst growth in ADPKD mice
- Double knockout of Pkd1 and Pkd2 gene inhibits renal cyst growth in ADPKD mice
- Long-term deletion of Pkd1 gene delayed fibrosis triggered renal cyst growth in
ADPKD mice
Abstract

Mutations in *PKD1* (encoding polycystin-1) or *PKD2* (encoding polycystin-2) gene cause autosomal dominant polycystic kidney disease (ADPKD), however high levels of polycystins are detected in renal tissues of ADPKD patients. Animal studies showed that loss and gain of function of polycystins are both pathogenic and can induce cystic phenotype in the kidney, which are associated with enhanced renal fibrosis. Recent studies showed that increased expression of polycystins contributes to organ fibrosis. However, the role of polycystins in renal tubulointerstitial fibrosis remains unclear. In this study, we demonstrated that polycystin-1 or polycystin-2 was highly expressed in the kidney of two different fibrotic mouse models and positively correlated with expression of collagen-I. Pharmaceutical inhibition of polycystin-2 with triptolide or genetic knockout of polycystin-2 reduced the expression of epithelial-mesenchymal transition (EMT) markers and deposition of extracellular matrix proteins in fibrotic kidneys. Similarly, conditional knockout of *Pkd1* gene also attenuated renal fibrosis in mouse models. Thus, we further hypothesized that inhibition of polycystins delays cyst growth by mitigating renal fibrosis. Here, we showed that polycystin-1 or polycystin-2 was up-regulated in *Pkd2* or *Pkd1* mice respectively and tightly correlated with the growth of renal cysts and fibrosis development. Genetic deletion of both polycystin-1 and polycystin-2 retarded cyst growth in *Pkd1* or *Pkd2* mice. Finally, we deleted *pkd1* gene in a fibrosis triggered adult ADPKD mouse model at different time point before or after the fibrotic injury. We showed that early and long-term inactivation of *Pkd1* delayed fibrosis triggered
renal cyst growth in adult *Pkd1* mice as compared with mice with late and short-term inactivation of *Pkd1* gene. We conclude that tubular obstruction induced polycystin up-regulation is pro-fibrotic and accelerates cyst growth through enhancing renal interstitial fibrosis in ADPKD mice. Our study indicates that ADPKD is caused by both loss and gain function of polycystins. Reduction of the aberrant upregulation of polycystins in cystic kidneys is a therapeutic option for ADPKD patients.
Introduction

Chronic kidney disease (CKD) is a worldwide health concern affecting more than 10% of global population with a high mortality and morbidity (1). Renal fibrosis is the common pathway of various CKD progressing to end stage renal disease regardless of its original causes (1). Hallmarks of renal fibrosis include excessive deposition of extracellular matrix (ECM) proteins (such as collagen-I, and fibronectin), over-expression of epithelial-mesenchymal transition (EMT) markers (such as N-cadherin, α-SMA and vimentin), activation of pro-fibrotic signaling pathways (such as the TGFβ/Smad3 signaling pathway) (2). Recent studies showed epigenetic alterations during the progression of renal fibrosis (3).

Polycystins were originally identified in autosomal dominant polycystic kidney disease (ADPKD), where mutations in PKD1 (encoding polycystin-1) or PKD2 (encoding polycystin-2) gene cause this disease (4). Deletion of Pkd1 or Pkd2 gene in mice can reproduce the cystic phenotype in the kidney, which indicates that loss of function of polycystins is pathogenic (5). Interestingly, several studies showed that exogeneous overexpression of polycystin-1 induced cyst formation in the mouse kidney, indicating that gain of function of polycystin-1 is also pathogenic (6-8). Abnormal renal fibrosis is observed in advanced ADPKD patients and mice with Pkd gene deletion, however transgenic mice with polycystin-1 overexpression also exhibit enhanced renal fibrosis (6, 9, 10). The direct effect of polycystins on renal fibrosis remain unknown.

In this study, we aimed to investigate the role of polycystins in renal
tubulointerstitial fibrosis and their underlying mechanisms in models of renal fibrosis induced by unilateral ureteral obstruction (UOO) and aristolochic acid using genetic and pharmacological approaches.
Results

The expression of polycystin-2 is increased in two mouse models of renal tubulointerstitial fibrosis

As the first step towards understanding the role of polycystins in renal fibrosis, we examined polycystin-2 expression in two mouse models of renal tubulointerstitial fibrosis in wild type (WT) induced by UUO and aristolochic acid I. Compared with sham kidneys, the expression of polycystin-2 was steadily increased from day 3 to 14 in the kidney following UUO, which was correlated with the expression of collagen-I over time (Figure 1A-1C). In the model of aristolochic acid nephropathy (AAN), polycystin-2 and collagen 1 began to increase at 3 days and further elevated at day 21 following aristolochic acid administration (Figure 1D-1F).

Inhibition of polycystin-2 attenuates renal tubulointerstitial fibrosis

Previous studies have shown that triptolide can bind to polycystin-2 and regulate its functions (11), we attempted to use triptolide as a molecular probe to examine the role of polycystin-2 in renal tubulointerstitial fibrosis in WT UUO mice. Masson staining showed that a massive deposition of interstitial collagens in UUO kidneys, and treatment with triptolide largely reduced extracellular matrix deposition (Figure 2A and 2B). Immunoblot analysis also indicated increased expression of ECM proteins (collagen-I) and EMT marker (α-SMA), and activated Smad3 (phosphorylated Smad3, pSmad3) in UUO kidneys and triptolide administration reduced expression of all those pro-fibrotic proteins (Figure 2C, and 2E-2G). Notably,
triptolide also inhibited expression of polycystin-2 in kidneys following UUO operation (Figure 2D and 2H). These data illustrate that triptolide protected kidneys against renal fibrosis and suggest that polycystin-2 upregulation is required for the development of renal fibrosis.

To verify the role of polycystin-2 in renal fibrosis, we examined the effect of Triptolide and polycystin-2 siRNA on the expression of EMT associated proteins in cultured human renal epithelial (HK2) cells. As shown in Figure 2I-2J, exposure of HK2 cells to TGF-β1 increased expression of fibronectin, N-cadherin and vimentin, and pSmad3, and presence of triptolide from 100 nM to 1000 nM reduced their expression (Figure 2I-2J), which is corresponding to its inhibition on polycystin-2 expression (Figure 2K and 2L). Similarly, transfection of PKD2 siRNA also reduced expression of these pro-fibrotic proteins, which was correlated with down-regulation of polycystin-2 (Figure 2M and 2P).

Since it has been reported that polycystin-2 is expressed in tissue fibroblasts (12), we also examined the effect of triptolide on the expression of proteins as described above in cultured normal rat kidney fibroblasts (NRK-49F). In line with our observations in HK2 cells, triptolide dose-dependently inhibited expression of these pro-fibrotic markers and polycystin-2 in this cell line (supplemental Figure 1A-1F).

Collectively, these data suggest that injury-induced upregulation of polycystin-2 may contribute to EMT, fibroblast activation and renal fibrosis.

Conditional knockout of polycystin-2 mitigates renal tubulointerstitial fibrosis in
mice

To confirm the pro-fibrotic role of polycystin-2, we generated Pkd2 conditional knockout mice. As shown in Figure 3A and 3B, heterozygous (Pkd2^{fl/+};Cre/Esr1^+) or homozygous (Pkd2^{fl/fl};Cre/Esr1^+) conditional knockout mice of Pkd2 exhibited reduced positive areas of Masson staining in UUO kidneys. Although the similar degree of dilated tubules was present in control (Pkd2^{fl/+};Cre/Esr1^-) or heterozygous Pkd2 knockout UUO kidneys without appearance of cysts, numerous small cysts (luminal diameter exceeding 50 μm) in addition of dilated tubules were observed in the kidney of homozygous Pkd2 knockout mice (Figure 3A). Immunoblot analysis showed partial reduction of Pkd2 expression in heterozygous and its absence in homozygous conditional knockout of Pkd2, which is corresponding to a different degree of pro-fibrotic markers (collagen-I, pSmad3, and α-SMA) (Figure 3C-3G).

The anti-fibrotic effect of polycystin-2 deletion was observed in AAN mouse models as well. As shown in Figure 3H-3N, mild renal interstitial fibrosis was seen in control (Pkd2^{fl/+};Cre/Esr1^+) AAN kidneys, as indicated by Masson staining and immunoblot analysis of collagen-I, pSmad3, and α-SMA (Figure 3H-3N). Heterozygous deletion of Pkd2 gene in Pkd2^{fl/+};Cre/Esr1^+ mice showed reduced deposition of extracellular matrix and expression of pro-fibrotic markers in AAN kidneys, which was correlated with downregulation of polycystin-2 (Figure 3H-3N).

Together, all these data indicate that polycystin-2 promotes EMT and is pro-fibrotic in diseased kidneys.
Polycystin-1 is increased in fibrotic kidneys and conditional deletion of \textit{Pkd1} gene attenuates renal tubulointerstitial fibrosis in mouse kidneys

Polycystin-2 intertwined with polycystin-1 in primary cilia mediates all the biological responses, we thus further examined the expression of polycystin-1 in the mouse model with renal tubulointerstitial fibrosis. Compared with sham kidneys, the expression of polycystin-1 was increased from day 3 to day 14 in UUO kidneys (Figure 4A-4C).

Using \textit{Pkd1} conditional knockout mice, we found that heterozygous (\textit{Pkd1}^{fl/+};\textit{Cre}/\textit{Esr1}+) or homozygous (\textit{Pkd1}^{fl/fl};\textit{Cre}/\textit{Esr1}+) conditional knockout of \textit{Pkd1} gene reduced the deposition of extracellular matrix in UUO kidneys as shown by Masson staining (Figure 4D-4E). Numerous small cysts were observed in homozygous \textit{Pkd1} knockout mice (Figure 4D). Heterozygous or homozygous conditional knockout of \textit{Pkd1} inhibited expression of polycystin-1 and pro-fibrotic markers (collagen-I, pSmad3, and α-SMA) in UUO kidneys as compared with control (\textit{Pkd1}^{fl/+};\textit{Cre}/\textit{Esr1}+) UUO kidneys (Figure 4F-4J). Collectively, our data indicate that polycystin-1 promotes renal tubulointerstitial fibrosis as well.

Genetic deletion of polycystin-2 delays disease progression in \textit{Pkd1} mice

ADPKD is characterized by enhanced renal tubulointerstitial fibrosis, and thus we further hypothesized that deletion of polycystins may attenuate renal fibrosis and delay ADPKD progression. \textit{Pkd1} or \textit{Pkd2} gene inactivation was induced by peritoneally injection of tamoxifen from postnatal day 25 to 28 (P25-P28), and mice
were sacrificed at P140 or P90 respectively (Figure 5A). Massive renal cysts were observed in Pkd1 mice (Pkd1<sup>fl/fl;Cre/Esr1</sup>) at P140 and in Pkd2 mice (Pkd2<sup>fl/fl;Cre/Esr1</sup>) at P90 (Figure 5B). Pkd2 mice were further crossed with Pkd1 mice. We found that heterozygous deletion of Pkd2 (Pkd2<sup>fl/+:Pkd1<sup>fl/fl;Cre/Esr1</sup></sup>) gene inhibited cyst growth in Pkd1 mice (Figure 5B). Two kidney weight/total body weight (2KW/TBW) ratio, blood urea nitrogen (BUN) and creatinine (CREA) levels were assessed (Figure 5C). Pkd2 mice has more severe phenotype compared to Pkd1 mice in this study, and we only observed significant increase in 2KW/TBW ratio but not in BUN or CREA levels in Pkd2 mice as compared with that in control mice (Pkd1<sup>fl/fl;Cre/Esr1</sup>) (Figure 5C). The 2KW/TBW ratio in Pkd2<sup>fl/+:Pkd1<sup>fl/fl;Cre/Esr1</sup></sup> mice was not significant lower than that in Pkd1 mice but lower than that in Pkd2 mice (Figure 5C).

**Long-term inactivation of Pkd1 delayed fibrosis triggered renal cyst growth in adult Pkd1 mice**

Renal injury and inactivation of both allele of ADPKD genes are third hits required for cystogenesis in adult ADPKD mice (13, 14). We inactivated Pkd1 gene in adult (8 weeks of age) Pkd1 mice at one week before aristolochic acid I (AAI, 5 mg/kg body weight) injection (13wk model) and sacrificed mice at 13 weeks after AAI injection (13 weeks after three hits) (Figure 6A). In another protocol (3+10wk model), Pkd1 gene was inactivated in adult Pkd1<sup>fl/fl;Cre/Esr1</sup> mice at three weeks after AAI injection, and mice were sacrificed at 10 weeks after Pkd1 gene inactivation (10 weeks after three hits) (Figure 6A). HE staining showed that no renal cyst was
observed in normal saline treated control $Pkd1^{fl/fl};\text{Cre/Esr1}^+$ mice (Figure 6B). Numerous small renal cysts were observed in mice with 13 weeks long-term $Pkd1$ inactivation, and surprisingly more cysts were formed in $Pkd1$ mice with short-term gene inactivation (3+10wk model) (Figure 6B). Compared with normal saline treated control $Pkd1^{fl/fl};\text{Cre/Esr1}^+$ mice, kidney weight but not BUN or CREA levels were increased in mice with 13 weeks long-term $Pkd1$ inactivation, which were further increased in $Pkd1$ mice with short-term gene inactivation (Figure 6C).
Discussion

In the current study, we investigated the role of polycystins in renal tubulointerstitial fibrosis. We conclude that polycystins are pro-fibrotic in injured kidneys, which is supported by the following observations: (1) polycystin-1 and polycystin-2 were up-regulated in two different mouse models of renal fibrosis, which was positively correlated with the expression of ECM protein collagen-I; (2) inhibition of polycystin-2 by triptolide or siRNA reduced expression of pro-fibrotic markers in cultured renal epithelial cells; (3) pharmaceutical or genetic inhibition of polycystin-2 reduced partial EMT and renal fibrosis in UUO and AAN mouse models; (4) conditional knockout of Pkd1 gene reduced pro-fibrotic marker expression and ECM accumulation in fibrotic kidneys.

Polycystin-1 and polycystin-2 form a transmembrane complex and are located in the primary cilia functioning as a calcium channel, which can sense external stimuli (12). Recent studies showed that primary cilia play an important role in organ fibrosis (15). Conditional knockout of ciliary proteins such as IFT88 or polycystin-1 attenuates fibrosis in injured lungs or hearts (12, 16). In line with these studies, inhibition or conditional knockout of the functional ciliary protein prolycystin-1 or polycystin-2 in injured kidneys also attenuated renal tubulointerstitial fibrosis, implying that primary cilia are required for renal tubulointerstitial fibrosis. Targeting ciliary genes or primary cilium related signaling pathways may be a new strategy to prevent or treat renal tubulointerstitial fibrosis.

Previous studies showed that renal fibrosis is increased in Pkd1 or Pkd2 deleted
kidneys after renal ischemia reperfusion injuries (IRI) (17, 18). Nevertheless, the genetic animals and animal models in these two studies were different from ours. In these two studies, *Pkd1* or *Pkd2* gene was globally knockout, which led to a different baseline before the surgery, such as an increased cell proliferation in the kidney of knockout mice as compared with that in wide type mice (17, 18). We used conditional knockout mice in this study, and to keep the same baseline condition, we only inactivated *Pkd* gene at one week before kidney injury. Second, we used UUO and AAN models in this study, which are two classical models to study renal tubulointerstitial fibrosis. The pathogenesis of renal tubulointerstitial fibrosis in UUO, AAN and IRI models are different, which may lead to different renal outcomes in investigating the role of polycystins in renal fibrosis (19-21).

Partial EMT is an important mechanism underlying renal tubulointerstitial fibrosis (22). Under this pathological condition, renal tubular epithelial cells express profibrotic markers but do not migrate into interstitial areas (22). In this study, we showed that pharmacological inhibition or genetic deletion of polycystins reduced expression of EMT markers such as *α*-SMA, N-cadherin and vimentin in fibrotic kidneys and in TGF-β stimulated human renal epithelial cells, suggesting that polycystins are engaged in EMT. EMT also plays an important role in cancer progression (23). It has been reported that the cancer risk in ADPKD recipient is lower than that in non-ADPKD recipient after renal transplantation, however the underlying biological mechanism is currently unknown (24). Thus, it would be interesting to study whether polycystin-mediated EMT is involved in the pro-tumor
action of ADPKD genes.

ADPKD is caused by heterozygous loss of polycystins (25). Paradoxically, polycystins are upregulated in kidney tissues of ADPKD patients, and thus studies on the gain of function of polycystins in kidney diseases is also important to understand the pathogenesis of ADPKD (6, 8). Based on the finding that polycystin overexpression is pro-fibrotic in kidney disease, we further hypothesized that reduction of the aberrant upregulation of polycystins may delay ADPKD progression. Here we showed that heterozygous deletion of polycystin-2 inhibited cyst growth in *Pkd1* mice. Interestingly, we further showed that long-term inactivation of polycystin-1 delayed fibrotic injury induced cyst growth in adult *Pkd1* mice as compared with *Pkd1* mice with short-term inactivation of polycystin-1.

A recent study showed that re-expression of *Pkd* genes reversed the progression of cystic kidney development in mice, suggesting that recovery of the lost *PKD* gene expression to normal levels by genetic therapy is a promising strategy for human ADPKD patients (26). Our study indicates that aberrant up-regulation of polycystins is pro-cystic and reduction of *Pkd* gene dosage slows cyst growth in ADPKD mice. Thus, properly control *PKD* gene dosage by either re-expression of the losted *PKD* gene to normal levels or reduction of upregulated polycystins could reverse or delay ADPKD progression in patients.

We conclude that tubular obstruction induced polycystin up-regulation is pro-fibrotic and accelerates cyst growth through enhancing renal interstitial fibrosis in ADPKD mice. Our study indicates that ADPKD is caused by both loss and gain
function of polycystins. Reduction of the aberrant upregulation of polycystins in
cystic kidneys is a therapeutic option for ADPKD patients.
Materials and Methods

Animals

Only male mice were used in animal studies. Wide type (WT) C57BL/6 mice (SPF grade, 20-25g) were purchased from Shanghai SLAC Laboratory Animal Co., Ltd. Pkd1<sup>fl/fl</sup> mice were obtained from Prof. Rudolf Wüthrich in University of Zurich, which were originally from the lab of Professor Gregory Germino in Johns Hopkins University School of Medicine (27). C57/BL6 Pkd1<sup>fl/fl</sup> mice were crossed with C57/BL6 tamoxifen-Cre (B6. Cg-Tg [Cre/Esr1]) 5Amc/J mice (stock 004682; Jackson Laboratories) as described previously (28). Pkd2 conditional knockout mice with exon 3 deletion have cystic phenotype in the kidney (29). CRISPR/Cas9 technology was used to generate a mouse with loxP sites flanking exon 3 of the Pkd2 gene by Shanghai Model Organisms Center. Pkd2<sup>fl/fl</sup> were crossed with tamoxifen-Cre mice to generate Pkd2<sup>fl/fl;Cre/Esr1</sup> mice. Animals were housed in the animal facility of Shanghai University of Traditional Chinese Medicine according to local regulations and guidelines. Animal experiments were approved by the ethic committee of Shanghai University of Traditional Chinese Medicine (PZSHUTCM18102604).

Genotyping

Genomic DNA was prepared from mouse tail by using animal genomic DNA quick extraction kit (D0065M, Beyotime Biotech, Nantong, China) as described in the manufacturer’s instructions. PCR genotyping was performed using the following primers: Pkd2-F, GTACACCTGTGCAGCACTCA; Pkd2-R, GGAGCTCATCATGCCGTAGG; CRE-F, ATTGCTGTC ACTTGGTCGTGGC; CRE-R, GGAAAATGCTTCTGTCGTTTG; Pkd1-F,
CCTGCCTTGCTCTACTTTCC; PKD1-R, AGGGCTTTTCTTGCTGGTCT; Details regarding PCR conditions are available upon request.

Experimental Animal Protocol

UUO operation was performed through twice ligation of the left ureter with 4-0 nylon sutures. WT animals were sacrificed at day 3, 7 or 14 in a time-course experiment (n=5-6 for each time point). For interventional study, WT mice were randomly divided into four groups: 1) Sham/Vehicle (n=6), 2) Sham/triptolide (n=7), 3) UUO/Vehicle (n=7), and 4) UUO/triptolide (n=7) group. The stock of triptolide (Topscience, T2179, Shanghai, China) was dissolved in DMSO and further diluted in normal saline as working solution. Sham or UUO mice were treated with vehicle or 0.25 mg/kg triptolide daily by intraperitoneal (i.p.) injection for 10 days starting from day 0. Mice were sacrificed at day 10. Kidney samples were obtained for Western blotting or histological examinations. For conditional knockout mice (n= 7-9 mice per group), Cre recombinase activity was induced by intraperitoneally injection of tamoxifen (50 mg kg⁻¹ day⁻¹, Apexbio, B5965) for three consecutive days at one week before UUO operations. Conditional knockout mice at 8 weeks of age were subjected to UUO operation and were sacrifice at day14.

To induce aristolochic acid nephropathy in mice, one dose of aristolochic acid I (AAI, A9451, Sigma; 5 mg/kg body weight) or normal saline (NS) was peritoneally injected. WT animals were sacrificed at day 3, 7 or 21 in a time-course experiment (n=5-6 for each time point). Kidney tissues were collected. For conditional knockout mice (n= 6-8 mice per group), Cre recombinase activity was induced at 7 weeks of
age by intraperitoneally injection of tamoxifen for three consecutive days at one week before the first AAI injection (5 mg/kg body weight), which was followed by a second AAI injection after one week (5 mg/kg body weight). Mice were sacrificed at 21 days after the second AAI injection.

To induce cystogenesis, Pkd1 or Pkd2 gene was inactivated at postnatal day 25 (P25) by intraperitoneal injection of tamoxifen for three consecutive days in male mice, which were sacrificed at P140 or P90 respectively. In another experiment, adult Pkd1 mice were injected with AAI (5 mg/kg body weight) once at 8 weeks of age, Pkd1 gene was inactivated by intraperitoneal injection of tamoxifen for three consecutive days at one week before or three weeks after the AAI injection. Mice were sacrificed at 13 weeks after the AAI injection. Mouse kidneys and blood were collected for further analysis.

Cell Culture

Normal rat kidney 49F (NRK-49F) cells, a rat kidney interstitial fibroblast cell line, were purchased from national infrastructure of cell line resource, Chinese academy of medical sciences. To study the anti-fibrotic effect of triptolide, NRK-49F cells were seeded in 6-well plates to 40–50% confluence and were starved with DMEM/F12 medium containing 0.5% fetal bovine serum (FBS) overnight before the experiment. The next day, cells were refreshed with DMEM/F12 medium with 0.5% FBS and then were exposed to different concentrations of triptolide (10 nM, 100 nM, and 1000 nM) for 24h. Protein was extracted from cell lysates for further analysis.
HK2 renal proximal tubular epithelial cells were obtained from the Cell Bank of Shanghai Institute of Biological Sciences (Chinese Academy of Science). HK2 cells were seeded in 6-well plate to 40-50% confluence, which were starved overnight with DMEM/F12 medium containing 0.5% fetal bovine serum. On the next day, fresh medium containing 0.5% fetal bovine serum was changed, and then cells were exposed to 2.5 ng/ml TGF-β (Peprotech, Rocky Hill, NJ, USA) for 48h in the presence of various concentration of triptolide.

Nonsense control (NC) or human PKD2 siRNA were transfected by Lipofectamine 2000 (11668-027; Invitrogen) in HK2 cells using DMEM/F12 medium containing 10% fetal bovine serum according to the manufacturer’s instruction. Protein was extracted from cell lysates at 48h after transfection to assess the efficacy of PKD2 siRNA (supplemental Figure 2). In another experiment, fresh medium containing 0.5% FBS was changed on the second day after transfection, and then cells were exposed to 2.5 ng/ml TGF-β (Peprotech, Rocky Hill, NJ, USA) for 48h with or without triptolide. The NC siRNA sequences were as follows: forward, 5'-UUCUCCGAACGUGACACGU-3'; and reverse, 5'-ACGUGACACGUUCGAGAATT-3'. The human PKD2 siRNA sequences were as follows: forward, 5'-GGACAUAGCUCCAGAAGGATT-3'; and reverse, 5'-UCCUUUCUGGAGCUAUGUCCTT-3'.

**Hematoxylin-eosin and Masson’s Trichrome Staining**

Mouse kidneys were fixed and embedded in paraffin. Four-μm-thick sections of paraffin-embedded kidney tissue was stained with hematoxylin, and then with
ponceau red liquid dye acid complex, which was followed by incubation with phosphomolybdic acid solution. Finally, the tissue was stained with aniline blue liquid and acetic acid. Images were obtained with the use of a microscope (Nikon 80i, Tokyo, Japan).

**Western Blotting**

Cellular or kidney protein was extracted by using lysis buffer purchased from Beyotime Biotech (P0013, Nantong, China). The protein concentration was measured by using BCA Protein Assay Kit (P0012S, Beyotime Biotech, Nantong, China). Protein samples were dissolved in 5x SDS-PAGE loading buffer (P0015L, Beyotime Biotech, Nantong, China), which were further subjected to SDS-PAGE gel electrophoresis. After electrophoresis, proteins were electro-transferred to a polyvinylidene difluoride membrane (Merck Millipore, Darmstadt, Germany), which was incubated in the blocking buffer (5% non-fat milk, 20mM Tris-HCl, 150mMNaCl, PH=8.0, 0.01%Tween 20) for 1 hour at room temperature and was followed by incubation with anti-polycystin-1 (1:500, sc-130554, SantaCruz), anti-polycystin-2 (1:1000, 19126-1-AP, Proteintech), anti-polycystin-2 (1:1000, A3625, ABclonal), anti-KIF3A (1:500, SC-376680, SantaCruz), anti-fibronectin (1:1000, ab23750, Abcam), anti-pSmad3 (1:1000, ET1609-41, HUABIO), anti-Collagen I (1:1000, ab260043, Abcam), anti-α-SMA (1:1000, ET1607-53, HUABIO), anti-N-cadherin (1:1000, sc-59887, Santa Cruz), anti-vimentin (1:1000, R1308-6, HUABIO), anti-GAPDH (1:5000, 60004-1-lg, Proteintech), or anti-α-tubulin (1:1000, AF0001, Beyotime) antibodies overnight at 4°C. Binding of the primary antibody was detected
by an enhanced chemiluminescence method (SuperSignal™ West Femto, 34094, Thermo Fisher Scientific) using horseradish peroxidase-conjugated secondary antibodies (goat anti-rabbit IgG, 1:1000, A0208, Beyotime or goat anti-mouse IgG, 1:1000, A0216, Beyotime).

**Statistical Analysis**

Statistical analyses were performed by one-way ANOVA followed by a Dunnett's multiple comparisons test using GraphPad Prism version 5.0 (GraphPad, San Diego, CA). All data are expressed as means ± SD, and P < 0.05 was considered as statistically significant.
Conflict of Interest Statement
The authors have no conflicts of interest to declare.

Funding Sources
This work was supported by Key Disciplines Group Construction Project of Pudong Health Bureau of Shanghai (PWZxq2017-07); The Three Year Action Plan Project of Shanghai Accelerating Development of Traditional Chinese Medicine (ZY(2018-2020)-CCCX-2003-08); Shanghai Key Laboratory of Traditional Chinese Clinical Medicine (20DZ2272200), Shanghai, PR China; Scientific Research Foundation of Shanghai Municipal Commission of Health and Family Planning (201740193) to MW; National Natural Science Foundation of China (81873617; 82170747) to CY.

Author Contributions
CY funded the project. MW, SZ, JH, YJ, CY, DC conceived and coordinated the study. MW, SZ and JH wrote the paper. YW conducted the in vitro experiments. MW, YW, YJ, JL, DC, BT, MY and DH performed the animal experiments. YW performed and analyzed the Western blotting. All authors reviewed the results and approved the final version of the manuscript.
References


10. Song CJ, Zimmerman KA, Henke SJ, and Yoder BK. Inflammation and Fibrosis in


Figure legends

Fig. 1. Polycystin-2 is up-regulated in fibrotic kidneys.

(A-C) The time course of polycystin-2 expression in sham or unilateral ureteral obstruction (UOO) kidneys from wild type (WT) mice. The expression of collagen-I and polycystin-2 was analyzed by Western blotting and quantified. One representative of at least three independent experiments is shown. (D-F) The time course of polycystin-2 expression in aristolochic acid nephropathy (AAN) kidneys from WT mice. The expression of collagen-I and polycystin-2 in normal saline (NS) or AAN kidneys was analyzed by Western blotting and quantified. N=5-6 in each experimental group and one representative of at least three independent experiments is shown. NS represents not significant. **p<0.01. ***p<0.001.

Fig. 2. Pharmaceutical or genetic inhibition of polycystin-2 attenuates renal tubulointerstitial fibrosis.
WT mice received sham or UUO operation followed by treatment with vehicle or triptolide (TP) for 10 days and then were sacrificed at day 10. (A-B) Renal fibrosis was assessed by Masson’s trichrome staining and quantified. Scale bar represents 100 μm. (C-H) The expression of collagen-I, phosphorylated Smad3 (pSmad3), α-SMA and polycystin-2 was analyzed by Western blotting and quantified. (I-L) HK2 human renal epithelial cells were stimulated with TGF-β and treated with different concentration of TP for 48 hours. Cell lysates were collected, and Western blot analysis was performed to determine expression of polycystin-2, fibronectin, N-cadherin, vimentin, and pSmad3, which was further quantified. (M-P) HK2 cells
were transfected with nonsense control (NC) or PKD2 siRNA (siPKD2). On the second day, HK2 cells were stimulated with TGF-β for 48 hours. Cell lysates were collected, and Western blot analysis was performed to determine expression of polycystin-2, fibronectin, N-cadherin, vimentin, and pSmad3. N = 7-9 in each experimental group and one representative of at least three independent experiments is shown. NS represents not significant. *p < 0.05. **p < 0.01. ***p < 0.001.

Fig. 3. Conditional knockout of Pkd2 attenuates renal tubulointerstitial fibrosis in mice.
Control (Pkd2^{fl/+};Cre/Esr1^-), heterozygous (Pkd2^{fl/+};Cre/Esr1^+) or homozygous (Pkd2^{fl/fl};Cre/Esr1^+) Pkd2 conditional knockout mice received sham or UUO operation and were sacrificed at day 14. (A-B) Renal fibrosis was assessed by Masson’s trichrome staining. Scale bar represents 100 μm. (C-G) The expression of collagen-I, pSmad3, α-SMA and polycystin-2 was analyzed by Western blotting. To induce aristolochic acid nephropathy (AAN), control (Pkd2^{fl/+};Cre/Esr1^-) or heterozygous (Pkd2^{fl/+};Cre/Esr1^+) Pkd2 conditional knockout mice were injected intraperitoneally with aristolochic acid I (AAI) or normal saline (NS) once a week for 2 weeks. Pkd2 gene was inactivated at one week before AAI or NS injection. Mice were sacrificed at 3 weeks after the second AAI or NS injection. (H and J) Renal fibrosis was assessed by Masson’s trichrome staining and quantified. Scale bar represents 100 μm. (I, K, L, M) The expression of collagen-I, pSmad3, α-SMA and polycystin-2 was analyzed by Western blotting and further quantified. N/i=6-8 in each experimental group and one representative of at least three independent experiments is shown. *p/i<0.05. **p/i<0.01. ***p/i<0.001.

Fig. 4. Conditional knockout of Pkd1 attenuates renal tubulointerstitial fibrosis in injured kidneys induced by UUO operation.

(A-C) The time course of polycystin-1 expression in sham or UUO kidneys from WT
mice. The expression of collagen-I and polycystin-1 was analyzed by Western blotting and quantified. N = 5-6 in each experimental group and one representative of at least three independent experiments is shown. Control (Pkd1fl/fl;Cre/Esr1−), heterozygous (Pkd1fl/fl;Cre/Esr1+) or homozygous (Pkd1fl/fl;Cre/Esr1+) Pkd1 knockout mice received sham or UUO operation and were sacrificed at day 14. (D-E) Renal fibrosis was assessed by Masson’s trichrome staining. Scale bar represents 100 μm. (F-J) The expression of collagen-I, pSmad3, α-SMA and polycystin-1 was analyzed by Western blotting and quantified. One representative of at least three independent experiments is shown. N = 6-8 in each experimental group and one representative of at least three independent experiments is shown. *p < 0.05. **p < 0.01. ***p < 0.001.

Fig. 5. Deletion of polycystin retards disease progression in ADPKD mice.
(A). Pkd1 or Pkd2 gene was inactivated at postnatal day 25 (P25) by intraperitoneal injection of tamoxifen in male mice, which were sacrificed at P140 or P90 respectively. (B-C). Renal function, kidney weight, and cyst volume were assessed. NS represents not significant. *p < 0.05.
Fig. 6. Long-term deletion of polycystin delays disease progression in fibrosis triggered adult ADPKD mice.

(A). Renal injury was established by injection of AAI in male Pkd1 mice at week 8, and Pkd1 gene was inactivated at one week before or three weeks after the kidney injury (three hits). Mice were sacrificed at 13 weeks after the kidney injury. (E-F). Renal function, kidney weight, and cyst volume were assessed. NS represents not significant. *p < 0.05.
Supplemental Fig. 1. Triptolide reduces the expression of polycystin-2 and pro-fibrotic markers in renal fibroblasts.

Normal rat renal fibroblasts (NRF-49F) were treated with different concentrations of triptolide (TP) for 24 hours, and cell lysates were collected. (A-F) Western blot analysis was performed to determine the expression of polycystin-2, fibronectin, N-cadherin, and vimentin, which was further quantified. One representative of at least three independent experiments is shown. NS represents not significant. *p < 0.05. **p < 0.01. ***p < 0.001.

Supplemental Fig. 2. Transfection efficiency of PKD2 siRNA in HK2 cells.

HK2 cells were transfected with NC or PKD2 siRNA. On the second day, HK2 cells were stimulated with TGF-β for 48 hours. Cell lysates were collected, and Western blot analysis and its quantification were performed to measure the expression of polycystin-2. One representative of at least three independent experiments is shown. **p < 0.01.